Heart Failure Outcomes and Empagliflozin Effects in Patients with Heart Failure and Reduced Ejection Fraction in Sinus Rhythm or Atrial Fibrillation: Data from EMPEROR-Reduced
In HFrEF, AF did not significantly modify outcomes after adjustment and did not associate with eGFR slopes. Empagliflozin reduced outcomes, eGFR decline and improved QoL regardless of AF or SR and probably reduced incident AF.
Authors
- Milton Packer
- Amr Abdin (ORCID: https://orcid.org/0000-0003-0847-1694)
- Martina Brueckmann (ORCID: https://orcid.org/0000-0003-1215-0746)
- Anne Pernille Ofstad (ORCID: https://orcid.org/0000-0003-2714-0102)
- Elke Schueler (ORCID: https://orcid.org/0000-0002-5955-8303)
- Christoph Wanner (ORCID: https://orcid.org/0000-0001-9507-5301)
- João Pedro Ferreira (ORCID: https://orcid.org/0000-0003-2422-4730)
- Michael Böhm (ORCID: https://orcid.org/0000-0003-1208-8647)
- Stefan D. Anker (ORCID: https://orcid.org/0000-0003-3331-7314)
- Stuart J. Pocock
- Faïez Zannad
- Javed Butler
Institutions
- Boehringer Ingelheim (Germany) (DE)
- Inserm (FR)
- University of Mannheim (DE)
- Universidade do Porto (PT)
- National and Kapodistrian University of Athens (GR)
- Heidelberg University (DE)
- Baylor University Medical Center (US)
- University of Mississippi (US)
- Boehringer Ingelheim (Norway) (NO)
- London School of Hygiene & Tropical Medicine (GB)
- Universitätsklinikum des Saarlandes (DE)
- Baylor Medical Center at Garland (US)
- Boehringer Ingelheim (Egypt) (EG)
- Universitätsklinikum Würzburg (DE)
- German Centre for Cardiovascular Research (DE)
- Reference Institute for Bioanalytics (DE)
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
- Boehringer Ingelheim (China) (CN)
- University Medical Centre Mannheim (DE)
- French Clinical Research Infrastructure Network (FR)
- Imperial College London (GB)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- European Journal of Heart Failure
- Published
- 2025-09-16
- DOI
- https://doi.org/10.1002/ejhf.70021
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Eli Lilly and Company
- AstraZeneca
- Sanofi
- Gilead Sciences
- CSL Behring
- Boston Scientific Corporation
- LivaNova
- Amarin Corporation
- Cytokinetics
- Impulse Dynamics
- Moderna
- Deutsche Forschungsgemeinschaft
- Novo Nordisk
- Servier
- Akebia Therapeutics
- Abbott Vascular
- Relypsa